GleamWall
中文EN

SGMOQ SANGAMO THERAPEUTICS, INC

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1001233 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-31.6%
TTM net income YoY-25.5%
TTM EPS YoY10.2%
Revenue 3-yr CAGR-29.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-306.5%
Net margin-310.8%
FCF margin-246.0%
EBITDA margin-296.5%

Returns

ROE-2,891.8%
ROA-152.4%
ROIC (approx.)—
Asset turnover0.49x

Leverage & solvency

Liabilities / assets123.9%
Debt / equity—
Current ratio0.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-31.9%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-30
Income statement
Revenue$1.44M$14.23M$581,000$18.31M$6.44M$7.55M$49.41M$356,000
R&D expense$26.57M$31.44M$28.14M$27.08M$26.01M$23.68M$27.73M$24.22M
SG&A expense$6.82M$7.76M$7.99M$9.08M$10.06M$9.87M$11.05M$12.04M
Operating income-$31.95M-$38.20M-$35.55M-$17.86M-$29.63M-$25.99M$10.63M-$37.08M
Pretax income-$31.00M-$37.97M-$35.09M-$19.96M-$30.48M-$23.82M$10.76M-$36.05M
Income tax$0-$553,000-$161,000$27,000$119,000-$427,000$88,000$74,000
Net income-$31.00M-$37.42M-$34.93M-$19.99M-$30.60M-$23.40M$10.67M-$36.13M
EBITDA-$31.23M-$37.24M-$34.56M-$16.86M-$28.61M-$24.75M$11.85M-$35.84M
EPS (basic)-0.08—-0.11-0.08-0.14—0.05-0.18
EPS (diluted)-0.08—-0.11-0.08-0.14—0.04-0.18
Weighted avg. shares (diluted)389.62M—304.27M256.95M220.27M—214.32M203.95M
Balance sheet
Cash & equivalents$27.59M$20.95M$29.62M$38.34M$25.18M$41.92M$39.20M$27.79M
Receivables$873,000$371,000$523,000$372,000$366,000$526,000$10.50M$581,000
Current assets$37.11M$35.83M$44.08M$49.89M$37.60M$51.69M$58.13M$40.08M
PP&E, net$10.32M$11.04M$14.79M$15.73M$16.88M$17.89M$19.15M$20.62M
Goodwill—————$0——
Intangibles—————$0——
Total assets$59.97M$59.74M$88.64M$97.56M$86.17M$101.64M$111.26M$93.01M
Current liabilities$53.13M$42.47M$50.12M$47.66M$49.56M$45.80M$43.16M$39.01M
Total liabilities$78.92M$74.01M$82.40M$77.96M$81.26M$78.86M$72.13M$69.32M
Shareholders' equity-$18.95M-$14.27M$6.24M$19.60M$4.91M$22.77M$39.13M$23.69M
Shares outstanding—350.69M———212.84M——
Cash flow statement
Operating cash flow-$19.28M-$24.40M-$28.50M-$18.16M-$26.15M-$3.35M$11.76M-$26.88M
Capital expenditure$13,000$14,000$64,000$24,000$0$152,000$115,000$0
Free cash flow-$19.30M-$24.42M-$28.56M-$18.18M-$26.15M-$3.50M$11.64M-$26.88M
Investing cash flow-$13,000-$14,000-$64,000-$24,000$0$1.32M$233,000$127,000
Financing cash flow$26.70M$14.80M$19.20M$28.61M$8.13M$6.99M-$203,000-$533,000
Depreciation & amortization$719,000$959,000$989,000$993,000$1.02M$1.24M$1.22M$1.24M
Stock-based compensation$992,000$2.13M$2.13M$2.23M$2.60M$3.28M$3.31M$3.06M

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.